TY - JOUR
T1 - The effect of parathyroid hormone (1–84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis
AU - Pepe, J.
AU - Cipriani, C.
AU - Cantatore, F. P.
AU - Fabbri, A.
AU - Pola, E.
AU - Vinicola, V.
AU - Raimo, O.
AU - Biamonte, F.
AU - Pascone, R.
AU - Ferrara, C.
AU - Minisola, S.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Purpose: To investigate the effect of 18 months’ parathyroid hormone 1–84 (PTH 1–84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis. Methods: Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1–84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study. Results: At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1–84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1–84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94). Conclusions: PTH (1–84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
AB - Purpose: To investigate the effect of 18 months’ parathyroid hormone 1–84 (PTH 1–84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis. Methods: Thirty-seven postmenopausal women with osteoporosis (mean age 72.9 ± 8.1 years old) and 23 healthy controls (mean age 68.9 ± 9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1–84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study. Results: At baseline, there were no differences considering anthropometric parameters, co-morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 ± 259.7 vs. 260.3 ± 184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 ± 1.7 vs. 5.7 ± 1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1–84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1–84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 ± 1.6 vs. 6.0 ± 1.5 pg/ml, p = 0.53) and VEGF (260.3 ± 184.3 vs. 257.4 ± 107.1 pg/ml, p = 0.94). Conclusions: PTH (1–84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
KW - Bone morphogenetic protein 4
KW - Osteoporosis
KW - Parathyroid hormone 1–84
KW - Vessel endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85019164033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019164033&partnerID=8YFLogxK
U2 - 10.1007/s40618-017-0636-8
DO - 10.1007/s40618-017-0636-8
M3 - Article
AN - SCOPUS:85019164033
VL - 40
SP - 663
EP - 667
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 6
ER -